Evidence map›Paper›PMID 24707491›Full record

ReviewBioMed research international2014

Extracellular vesicles in prostate cancer: new future clinical strategies?

Ilaria Giusti, Vincenza Dolo

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy.International journal of molecular sciences · 2020
    Review
  8. Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. PSA and beyond: alternative prostate cancer biomarkers.Cellular oncology (Dordrecht, Netherlands) · 2016
    Review
  15. Review
  16. Noncoding RNAs as novel biomarkers in prostate cancer.BioMed research international · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ilaria GiustiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, Via Vetoio-Coppito 2, I-67100 L'Aquila, Italy.ORCID 0000-0002-7982-471X
Vincenza DoloDepartment of Life, Health and Environmental Sciences, University of L'Aquila, Via Vetoio-Coppito 2, I-67100 L'Aquila, Italy.ORCID 0000-0003-0424-6676
University of L'Aquila · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is the most common cancer--excluding skin tumors--in men older than 50 years of age. Over time, the ability to diagnose PCa has improved considerably, mainly due to the introduction of prostate-specific antigen (PSA) in the clinical routine. However, it is important to take into account that although PSA is a highly organ-specific marker, it is not cancer-specific. This shortcoming suggests the need to find new and more specific molecular markers. Several emerging PCa biomarkers have been evaluated or are being assessed for their potential use. There is increasing interest in the prospective use of extracellular vesicles as specific markers; it is well known that the content of vesicles is dependent on their cellular origin and is strongly related to the stimulus that triggers the release of the vesicles. Consequently, the identification of a disease-specific molecule (protein, lipid or RNA) associated with vesicles could facilitate their use as novel biological markers. The present review describes several in vitro studies that demonstrate the role of vesicles in PCa progression and several in vivo studies that highlight the potential use of vesicles as PCa biomarkers.

Indexed as

Biomarkers, TumorDisease ProgressionHumansMaleProstate-Specific AntigenProstatic NeoplasmsBiomarkers, TumorProstate-Specific Antigen

Identifiers

PMID24707491
PMCPMC3950949
OpenAlexW2059103382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.